Overview

Study of Omalizumab in Moderate to Severe Bronchial Asthma

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Collaborator:
Daiichi Sankyo Co., Ltd.
Treatments:
Omalizumab